Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of “Buy” by Brokerages

Spyre Therapeutics, Inc. (NASDAQ:SYREGet Free Report) has been given a consensus recommendation of “Buy” by the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $39.20.

Several analysts have issued reports on the stock. Wells Fargo & Company upgraded shares of Spyre Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $12.00 to $35.00 in a research note on Friday, March 1st. Stifel Nicolaus increased their price objective on Spyre Therapeutics from $36.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, March 26th.

Read Our Latest Stock Analysis on SYRE

Spyre Therapeutics Stock Performance

NASDAQ:SYRE opened at $33.30 on Tuesday. Spyre Therapeutics has a 52-week low of $2.66 and a 52-week high of $47.97. The company’s fifty day moving average is $34.07. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -0.44 and a beta of 2.88.

Spyre Therapeutics (NASDAQ:SYREGet Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($2.28) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($1.80). On average, sell-side analysts predict that Spyre Therapeutics will post -2.36 EPS for the current fiscal year.

About Spyre Therapeutics

(Get Free Report

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).

Featured Stories

Analyst Recommendations for Spyre Therapeutics (NASDAQ:SYRE)

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.